US Patent 10213390 Treatment of fragile X syndrome with cannabidiol
Patent 10213390 was granted and assigned to Zynerba Pharmaceuticals on February, 2019 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 10213390 Treatment of fragile X syndrome with cannabidiol
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
